Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study

  • Authors:
    • George P. Stathopoulos
    • Teni Boulikas
    • Maria Vougiouka
    • Sotirios K. Rigatos
    • John G. Stathopoulos
  • View Affiliations

  • Published online on: May 1, 2006     https://doi.org/10.3892/or.15.5.1201
  • Pages: 1201-1204
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present trial is a phase I-II study based on a new liposomal cisplatin (lipoplatin). Previous preclinical and clinical data (phase I pharmacokinetics) led to the investigation of a combined treatment modality involving lipoplatin and gemcitabine. The gemcitabine dose was kept standard at 1000 mg/m2 and the lipoplatin dose was escalated from 25 mg/m2 to 125 mg/m2. The treatment was administered to advanced pretreated pancreatic cancer patients who were refractory to previous chemotherapy which included gemcitabine. Lipoplatin at 125 mg/m2 was defined as dose limiting toxicity (DLT) and 100 mg/m2 as the maximum tolerated dose (MTD) in combination with 1000 mg/m2 of gemcitabine. Preliminary objective response rate data showed a partial response in 2/24 patients (8.3%), disease stability in 14 patients (58.3%) for a median duration of 3 months (range 2-7 months) and clinical benefit in 8 patients (33.3%). Liposomal cisplatin is a non-toxic alternative agent to bare cisplatin. In combination with gemcitabine, it has an MTD of 100 mg/m2 and shows promising efficacy in refractory pancreatic cancer.

Related Articles

Journal Cover

May 2006
Volume 15 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK and Stathopoulos JG: Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study. Oncol Rep 15: 1201-1204, 2006.
APA
Stathopoulos, G.P., Boulikas, T., Vougiouka, M., Rigatos, S.K., & Stathopoulos, J.G. (2006). Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study. Oncology Reports, 15, 1201-1204. https://doi.org/10.3892/or.15.5.1201
MLA
Stathopoulos, G. P., Boulikas, T., Vougiouka, M., Rigatos, S. K., Stathopoulos, J. G."Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study". Oncology Reports 15.5 (2006): 1201-1204.
Chicago
Stathopoulos, G. P., Boulikas, T., Vougiouka, M., Rigatos, S. K., Stathopoulos, J. G."Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study". Oncology Reports 15, no. 5 (2006): 1201-1204. https://doi.org/10.3892/or.15.5.1201